Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines

Chemotherapy

Volumn 54, Issue 3, 2008, Pages 166-175

  Nagai, Shinjiro ^a   Takenaka, Kazumasa ^a   Sonobe, Makoto ^a   Wada, Hiromi ^a   Tanaka, Fumihiro ^a,b  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Combination chemotherapy; Gemcitabine; Lung cancer; Pemetrexed; Pleural mesothelioma

Indexed keywords

CARRIER PROTEIN; FOLYLPOLYGLUTAMATE SYNTHASE; GEMCITABINE; MESSENGER RNA; PEMETREXED; REDUCED FOLATE CARRIER 1; THYMIDYLATE SYNTHASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIVITY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; LUNG NON SMALL CELL CANCER; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; PEPTIDE SYNTHASES; PLEURAL NEOPLASMS; REPLICATION PROTEIN C; RNA, MESSENGER; THYMIDYLATE SYNTHASE; TIME FACTORS;

EID: 46449098514     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000140360     Document Type: Article

References (49)

1. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M, Schultz RM: LY231514, a pyrrolo [2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-1123.
2. Zhao R, Babani S, Gao F, Liu L, Goldman ID: The mechanism of transport of the multitargeted antifolate MTA-LY231514, and its cross-resistance pattern in cell with impaired transport of methotrexed. Clin Cancer Res 2000;6:3687-3695.
3. Taylor EC, Kuhnt D, Shih C, Rinzel SM, Grindey GB, Barredo J, Jannatipour M, Moran RG: A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl] benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 1992;35:4450-4454.
4. Britten CD, Izbicka E, Hilsenbeck S, Lawrence R, Davidson K, Cerna C, Gomez L, Rowinsky EK, Weitman S, Von Hoff DD: Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay. Cancer Chemother Pharmacol 1999;44:105-110.
5. Rusthoven JJ, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B, Iglesias J: Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999;17:1194-1199.
6. Miles DW, Smith IE, Coleman RE, Calvert AH, Lind MJ: A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. Eur J Cancer 2001;37:1366-1371.
7. Spielmann M, Martin M, Namer M, duBois A, Unger C, Dodwell DJ: Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis. Clin Breast Cancer 2001;2:47-51.
8. Miller KD, Picus J, Blanke C, John W, Clark J, Shulman LN, Thornton D, Rowinsky E, Loehrer PJ: Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann Oncol 2000;11:101-103.
9. Bajetta E, Celio L, Buzzoni R, Ferrari L, Marchiano A, Martinetti A, Longarini R, Becerra C, Ilardi C, John W: Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer. Ann Oncol 2003;14:1543-1548.
10. Meriggi F, Di Biasi B, Caliolo C, Zaniboni A: The potential role of pemetrexed in gastrointestinal cancer. Chemotherapy 2008;54:1-8.
11. Cripps C, Burnell M, Jolivet J, Batist G, Lofters W, Dancey J, Iglesias J, Fisher B, Eisenhauer EA: Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study. Ann Oncol 1999;10:1175-1179.
12. John W, Picus J, Blanke CD, Clark JW, Schulman LN, Rowinsky EK, Thornton DE, Loehrer PJ: Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. Cancer 2000;88:1807-1813.
13. Pivot X, Raymond E, Laguerre B, Degardin M, Cals L, Armand JP, Lefebvre JL, Gedouin D, Ripoche V, Kayitalire L, Niyikiza C, Johnson R, Latz J, Schneider M: Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer 2001;85:649-655.
14. Steele JPC, Klabatsa A: Chemotherapy options and new advances in malignant pleural mesothelioma. Ann Oncol 2005;16:345-351.
15. Adjei AA:Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res 2004;10(suppl):4276s-4280s.
16. Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C, Burris H, Gatzemeier U, Blatter J, Symanowski JT, Rusthoven JJ: Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003;21:1556-1561.
17. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644.
18. Hanna N, Shepherd FA, Fossella FV, Pereira JR, Marinis FD, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
19. Meyer F, Lueck A, Hribaschek A, Lippert H, Ridwelski K: Phase I trial using weekly administration of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma. Chemotherapy 2004;50:289-296.
20. Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, Matano E, Boni C, Marangolo M, Failla G, Altavilla G, Adamo V, Ceribelli A, Clerici M, Di Costanzo F, Frontini L, Tonato M: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-4291.
21. Greco FA, Gray JR Jr, Thompson DS, Burris HA 3rd, Erland JB, Barton JH Jr, Litchy S, Houston GA, Butts JA, Webb C, Scott C, Hainsworth JD: Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a Minnie Pearl Cancer Research Network trial. Cancer 2002;95:1279-1285.
22. Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Samantas E, Boukovinas J, Fountzilas G, Skarlos D, Economopoulos T, Tsavdaridis D, Papakostas P, Bacoyiannis C, Dimopoulos M: Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2002;20:3578-3585.
23. Adjei AA, Erlichman C, Sloan JA, Reid JM, Pitot HC, Goldberg RM, Peethambaram P, Atherton P, Hanson LJ, Alberts SR, Jett J: Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 2000;18:1748-1757.
24. Monnerat C, Le Chevalier T, Kelly K, Obasaju CK, Brahmer J, Novello S, Nakamura T, Liepa AM, Bozec L, Bunn PA Jr, Ettinger DS: Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Clin Cancer Res 2004;10:5439-5446.
25. Ma CX, Nair S, Thomas S, Mandrekar SJ, Nikcevich DA, Rowland KM, Fitch TR, Windschitl HE, Hillman SL, Schild SE, Jett JR, Obasaju C, Adjei AA: Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5429-5437.
26. Treat J, Bonomi P, McCleod M, Christiansen NP, Mintzer DM, Monberg MJ, Ye Z, Chen R, Obasaju CK: Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial. Lung Cancer 2006;53:77-83.
27. Teicher BA, Chen V, Shih C, Menon K, Forler PA, Phares VG, Amsrud T: Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res 2000;6:1016-1023.
28. Tonkinson JL, Worzalla JF, Teng CH, Mendelsohn LG: Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 1999;59:3671-3676.
29. Tesei A, Ricotti L, De Paola F, Amadori D, Frassineti GL, Zoli W: In vitro schedule-dependent interactions between the multitargeted antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell lines. Clin Cancer Res 2002;8:233-239.
30. Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, de Klerk NH, Robinson BW: Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999;17:25-30.
31. Giovanetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R: Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005;68:110-118.
32. Tonkinson JL, Marder P, Andis SL, Schultz RM, Gossett LS, Shih C, Mendelsohn LG: Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis. Cancer Chemother Pharmacol 1997;39:521-531.
33. Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
34. van Triest B, Pinedo HM, van Hensbergen Y, Smid K, Telleman F, Schoenmakers PS, van der Wilt CL, van Laar JA, Noordhuis P, Jansen G, Peters GJ: Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin Cancer Res 1999;5:643-654.
35. Sigmond J, Backus HHJ, Wouters D, Temmink OH, Jansen G, Peters GL: Induction of resistance to the multitargeted antifolate pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 2003;66:431-438.
36. Liani E, Rothem L, Bunni MA, Smith CA, Jansen G, Assaraf YG:Loss of folylpoly-γ-glutamate synthase activity is a dominant mechanism of resistance to polyglutamation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer 2003;103:587-599.
37. Wang Y, Zhao R, Goldman ID: Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line. Biochem Pharmacol 2003;65:1163-1170.
38. Kim JH, Lee KW, Jung Y, Kim TY, Ham HS, Jong HS, Jung KH, Im SA, Kim TY, Kim NK, Bang YJ: Cytotoxic effects of pemetrexed in gastric cancer cells. Cancer Sci 2005;96:365-371.
39. Dempsey JA, Laigle DK, Schultz RM: Effect of the multitargeted antifolate (MTA, ALIMTA TM ) on human mesothelioma cell lines. Proc Am Assoc Cancer Res 2000;41:4.
40. Rinaldi DA, Kuhn JG, Burris HA, Dorr FA, Rodriguez G, Eckhardt SG, Jones S, Woodworth JR, Baker S, Langley C, Mascorro D, Abrahams T, Von Hoff DD: A phase I evaluation of mutitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 1999;44:372-380.
41. Ouellet D, Periclou AP, Johnson RD, Woodworth JR, Lalonde RL: Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer. Cancer Chemother Pharmacol 2000;46:227-234.
42. Smith PG, Marshman E, Newell DR, Curtin NJ: Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport. Br J Cancer 2000;82:924-930.
43. Kano Y, Akutsu M, Tsunoda S, Izumi T, Mori K, Fujii H, Yazawa Y, Mano H, Furukawa Y: Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro. Cancer Chemother Pharmacol 2004;54:505-513.
44. Rhee MS, Ryan TJ, Galivan J: Glutamyl hydrolase and the multitargeted antifolate LY231514. Cancer Chemother Pharmacol 1999;44:427-432.
45. Wang Y, Zhao R, Chattopadhyay S, Goldman ID: A novel folate transport activity in human mesothelioma cell lines with high affinity and specificity for the new-generation antifolate, pemetrexed. Cancer Res 2002;62:6434-6437.
46. Janne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, Bloss LP, Ye Z, Obasaju C, Kindler HL: An update of pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (pts) with malignant pleural mesothelioma (MPM): A phase II clinical trial. J Clin Oncol 2005;23(suppl 1):637s.
47. Hernández-Vargas H, Rodríguez-Pinilla SM, Julián-Tendero M, Sánchez-Rovira P, Cuevas C, Antón A, Ríos MJ, Palacios J, Moreno-Bueno G: Gene expression profiling of breast cancer cells in response to gemcitabine: NF-κB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat 2007;102:157-172.
48. Zhou B, Mo X, Liu X, Qiu W, Yen Y: Human ribonucleotide reductase M2 subunit gene amplification and transcriptional regulation in a homogeneous staining chromosome region responsible for the mechanism of drug resistance. Cytogenet Cell Genet 2001;95:34-42.
49. Leclerc GJ, Leclerc GM, Kinser TT, Barredo JC: Analysis of folylpoly-γ-glutamate synthetase gene expression in human B-precursor ALL and T-lineage ALL cells. BMC Cancer 2006;6:132.